

KINGSLEY ALFRED D  
 Form 4  
 August 02, 2017

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
 Expires: January 31, 2015  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
**KINGSLEY ALFRED D**

(Last) (First) (Middle)  
 150 E. 57TH STREET  
 (Street)

NEW YORK, NY 10022

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
**BIOTIME INC [BTX]**

3. Date of Earliest Transaction (Month/Day/Year)  
 07/31/2017

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director  10% Owner  
 Officer (give title below)  Other (specify below)  
 See Remarks

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Shares, no par value	07/31/2017		S	150,000 (1)	D \$ 2.8	5,781,555 (2)	D
Common Shares, no par value					1,143,346	I	By Greenbelt Corp.
Common Shares, no par value					375,351	I	By Greenway Partners, LP

Edgar Filing: KINGSLEY ALFRED D - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price or Value of Underlying Securities (Instr. 3 and 4)	
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to Purchase Common Shares	\$ 3.15					<u>(3)</u>	06/30/2022	Common Shares	50,000
Option to Purchase Common Shares	\$ 2.72					<u>(4)</u>	06/30/2021	Common Shares	50,000
Option to Purchase Common Shares	\$ 3.57					<u>(5)</u>	06/30/2020	Common Shares	50,000
Option to Purchase Common Shares	\$ 3.11					<u>(6)</u>	06/30/2019	Common Shares	50,000
Option to Purchase Common Shares	\$ 4.13					<u>(7)</u>	06/30/2018	Common Shares	50,000

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other

KINGSLEY ALFRED D  
150 E. 57TH STREET  
NEW YORK, NY 10022

X

See Remarks

## Signatures

/s/Alfred D.  
Kingsley

08/02/2017

\*\*Signature of  
Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
  - \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The securities were sold in a private transaction. Substantially all of the sale proceeds were invested in AgeX Therapeutics, Inc., a new subsidiary of BioTime.
  - (2) Does not include shares that Mr. Kingsley may acquire through the exercise of certain options.
  - (3) Will become exercisable in four equal quarterly installments after the date of grant on July 1, 2017 based upon continued service on the board of directors.
  - (4) Became exercisable in four equal quarterly installments after the date of grant on July 1, 2016.
  - (5) Became exercisable in four equal quarterly installments after the date of grant on July 1, 2015.
  - (6) Became exercisable in four equal quarterly installments after the date of grant on July 1, 2014.
  - (7) Became exercisable in four equal quarterly installments after the date of grant on July 1, 2013.

### Remarks:

Mr. Kingsley is Chairman of certain BioTime subsidiaries.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.